Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 77 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Nivo/Ipi Combination Therapy in Symptomatic Brain MetastasesTerminatedNCT02621515Phase 2
• Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedNCT02620423Phase 1
• Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic MelanomaActive, not recruitingNCT02617849Phase 2
• Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid TumoursCompletedNCT02617277Phase 1
• A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02616640Phase 1
• Combination of Interferon-gamma and Nivolumab for Advanced Solid TumorsCompletedNCT02614456Phase 1
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid TumorsActive, not recruitingNCT02608385Phase 1
• A Study of Pembrolizumab for Patients With Thymic Epithelial TumorCompletedNCT02607631Phase 2
• Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast CancerCompletedNCT02605915Phase 1
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal CancerActive, not recruitingNCT02600949Phase 1
• A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC PatientsCompletedNCT02599779Phase 2
• Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung CancerCompletedNCT02599454Phase 1
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02595944Phase 3
• Nivolumab in Treating Patients With High-Risk Kidney Cancer Before SurgeryTerminatedNCT02595918Phase 1
• MRI and PET to Assess Pembrolizumab ResponseTerminatedNCT02591654Early Phase 1
• A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)Status unknownNCT02588131Phase 2
• A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursCompletedNCT02586987Phase 1
• Trial of Chemoradiation and Pembrolizumab in Patients With Rectal CancerWithdrawnNCT02586610Phase 2
• ONO-4538 Study in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT02582125Phase 2
• Pembrolizumab in Untreated Extensive SCLCCompletedNCT02580994Phase 2
• Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe SepsisTerminatedNCT02576457Phase 1
• GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer PatientsCompletedNCT02575404Phase 1
• Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell CarcinomaCompletedNCT02575222Phase 1
• Pilot Study of Vigil™ + Pembrolizumab for Advanced MelanomaCompletedNCT02574533Phase 1
• A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic MalignanciesCompletedNCT02572687Phase 1
• PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian CancerActive, not recruitingNCT02571725Phase 1/2
• Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)CompletedNCT02565992Phase 1
• Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)TerminatedNCT02564380Phase 2
• Pembrolizumab in Muscle Invasive/Metastatic Bladder CancerActive, not recruitingNCT02560636Phase 1
• Neoadjuvant Nivolumab in GlioblastomaCompletedNCT02550249Phase 2
• MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)CompletedNCT02549651Phase 1
• Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
• Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced CancerCompletedNCT02546531Phase 1
• Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy RegimensActive, not recruitingNCT02537418Phase 1
• Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed GlioblastomaTerminatedNCT02530502Phase 1
• Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2
• MPDL3280A With Chemoradiation for Lung CancerActive, not recruitingNCT02525757Phase 2
• Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDCompletedNCT02523313Phase 2
• Adjuvant Durvalumab for Esophageal CancerStatus unknownNCT02520453Phase 2
• Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical StudyWithdrawnNCT02520245Phase 1
• A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid TumorsCompletedNCT02516527Phase 1
• A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic SyndromesCompletedNCT02508870Phase 1
• MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.CompletedNCT02503774Phase 1
• A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT02500407Phase 1/2
• Nivolumab in Patients With Recurrent Malignant MesotheliomaCompletedNCT02497508Phase 2
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung CancerWithdrawnNCT02495636Phase 2
• A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer PatientsCompletedNCT02492789Phase 1
• Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)TerminatedNCT02485990Phase 1
• MPDL3280A-treatment-IST-UMCGActive, not recruitingNCT02478099Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLCCompletedNCT02463994Early Phase 1
• A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisStatus unknownNCT02460068Phase 3
• Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02453620Phase 1
• A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic CancersTerminatedNCT02452268Phase 1
• Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasActive, not recruitingNCT02451982Phase 2
• A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)TerminatedNCT02446860Phase 2
• Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior TherapyActive, not recruitingNCT02432963Phase 1
• A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)CompletedNCT02431208Phase 1
• Phase I Clinical Trial of Cryoimmunotherapy Against Prostate CancerCompletedNCT02423928Phase 1
• Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinActive, not recruitingNCT02414269Phase 1/2
• A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedNCT02413827Phase 1/2
• A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02410512Phase 1
• Trial of SBRT With Concurrent Ipilimumab in Metastatic MelanomaCompletedNCT02406183Phase 1
• MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung CancerTerminatedNCT02400814Phase 1
• A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced MelanomaWithdrawnNCT02400385Phase 2
• Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1
• Study of REGN2810 (Anti-PD-1) in Patients With Advanced MalignanciesCompletedNCT02383212Phase 1
• Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedNCT02381314Phase 1
• HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIACompletedNCT02379520Phase 1
• Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesActive, not recruitingNCT02374242Phase 2
• Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or MedulloblastomaActive, not recruitingNCT02359565Phase 1
• A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid TumorsCompletedNCT02350673Phase 1
• A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaActive, not recruitingNCT02339571Phase 2/3
• Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2bCompletedNCT02339324Phase 1
• A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid TumorsCompletedNCT02323191Phase 1
• Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung CancerCompletedNCT02318771Phase 1
• Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1
• Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1
• Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)CompletedNCT02307149Phase 1
• Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic CancerStatus unknownNCT02305186Phase 1/2
• A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid TumorsCompletedNCT02304393Phase 1
• Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2
• Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475CompletedNCT02303366Phase 1
• Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid TumorsCompletedNCT02301130Phase 1
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
• Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
• A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedNCT02298153Phase 1
• Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMActive, not recruitingNCT02287428Phase 1
• Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant MelanomaCompletedNCT02275416Phase 1/2
• A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaCompletedNCT02272855Phase 2
• Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI CancersTerminatedNCT02268825Phase 1
• Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric CancerCompletedNCT02267343Phase 3
• A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck CancerCompletedNCT02262741Phase 1
• ONO-4538 Phase I Study in Patients With Solid TumorCompletedNCT02261298Phase 1
• A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid TumorsCompletedNCT02261220Phase 1
• Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid TumorsCompletedNCT02239900Phase 1
• A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid TumorsCompletedNCT02221960Phase 1
• Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryActive, not recruitingNCT02210117Early Phase 1

← Immune Checkpoint Inhibitors overview